The generics unit of Novartis, Sandoz, has launched a later stage trial with its bio similar version of Amgen's Enbrel. Collectively it is foremost position in generating the cheaper copies of complex biotech drugs.

As per recent reports, it has been revealed that GlaxoSmithKline (GSK) has acquired Okairos AG for _250 million. By making such a move, the company has strengthened its vaccine business, said experts.

Experts continued by affirming that the recent acquisition of Okairos AG clearly shows that GSK wants to progress further in developing innovative medicines.

In a move which indicates that Japan-based food, pharmaceuticals, and specialty chemicals manufacturer Ajinomoto is aiming at new global acquisitions, recent reports have revealed that the company has struck an acquisition deal - worth approximately $175 million - with San Diego-based Althea Technologies, a 1998-founded contract drug manufacturer.

It has been recently announced by drug maker Merck that their drug, which was considered to prevent heart attacks, has been found to be having some serious problems. Due to this, they are going to ask doctors across the world that they should not prescribe the drug anymore.